SCHEMBL23355695

SCHEMBL23355695

COC(=O)c1nccc(CO[Si](C)(C)C(C)(C)C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.36
KDM4E B2RXH2 3/20 0.33
ALOX15 P16050 2/20 0.33
AR P10275 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYSLTR1 Q9Y271 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KMT2A Q03164 2/20 0.33
ATR Q13535 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KDM6B O15054 1/20 0.33
KDM5C P41229 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
KDM3A Q9Y4C1 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.32
MRGPRX4 Q96LA9 2/20 0.32
ALOX5AP P20292 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25619986 0.80 MAPT (0.37) KDM4EALOX15ARL3MBTL1ALDH1A1
SCHEMBL31132665 0.78 KDM4E (0.48) KDM4EALOX15L3MBTL1CYSLTR1NPC1
SCHEMBL23355571 0.77 KDM4E (0.38) KDM4EALOX15L3MBTL1ALDH1A1KMT2A
SCHEMBL24323834 0.77 KDM4E (0.38) KDM4EALOX15ARL3MBTL1ALDH1A1
SCHEMBL31132768 0.77 HCRTR1 (0.39) BACE1KDM4EALOX15ARL3MBTL1
SCHEMBL31273643 0.76 CYP4F2 (0.43) KDM4EALOX15L3MBTL1ALDH1A1KMT2A
SCHEMBL7373737 0.76 KDM4E (0.38) KDM4EALOX15L3MBTL1ALDH1A1KDM6B
SCHEMBL8260068 0.76 MRGPRX4 (0.51) BACE1NPC1RAB9AIRAK4MRGPRX4
SCHEMBL15994295 0.74 AR (0.45) BACE1KDM4EALOX15ARL3MBTL1
SCHEMBL29468748 0.74 AR (0.45) BACE1KDM4EALOX15ARL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023103898-A1 COMPOUND HAVING CLK AND DYRK INHIBITORY ACTIVITIES, PREPARATION METHOD THEREFOR AND USE THEREOF 赛诺哈勃药业(成都)有限公司 2023-06-15 WO disclosed
US-20210355104-A1 ADENOSINE RECEPTOR BINDING COMPOUNDS NIKANG THERAPEUTICS, INC. (US) 2021-11-18 US disclosed
EP-3820474-A1 ADENOSINE RECEPTOR BINDING COMPOUNDS Nikang Therapeutics, Inc. (US) 2021-05-19 EP disclosed
CN-112423758-A Adenosine receptor binding compounds 尼康治疗公司 2021-02-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355104-A1 ADENOSINE RECEPTOR BINDING COMPOUNDS ADORA2A, ADORA1, ADORA3 BACE1 4304/4885KDM4E 3550/4885ALOX15 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.